PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

J M Wood, Guido Bold, Elisabeth Buchdunger, +23

PubMed

ImmunologyOral AdministrationPharmacotherapyTumor BiologyAngiogenesis +18

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

R.C. Hillig, Brice Sautier, Jens Schroeder, +19

Proceedings of the National Academy of Sciences

Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.

Gerhard Siemeister, Karin Weindel, Katja Mohrs, +3

PubMed

Vhl SyndromeRenal PathologyPathologyTumor BiologyAngiogenesis +14

Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells.

Bernhard Barleon, Gerhard Siemeister, Georg Martiny‐Baron, +3

PubMed

Endothelial CellsImmunologyPathologyTumor BiologyAngiogenesis +14

Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression

Günter Finkenzeller, Angelica Sparacio, Antje Technau, +2

Oncogene

ThrombopoiesisThrombosisProximal PromoterDevelopmental BiologyAngiogenesis +7

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking, +17

Molecular Cancer Therapeutics

Use of the Novel Plk1 Inhibitor ZK-Thiazolidinone to Elucidate Functions of Plk1 in Early and Late Stages of Mitosis

Anna Santamaría, Rüdiger Neef, Uwe Eberspächer, +9

Molecular Biology of the Cell

MitophagyCell DeathMolecular BiologyCytoskeletonCell Cycle +18

Mapping of the Sites for Ligand Binding and Receptor Dimerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor FLT-1

Bernhard Barleon, Frank Totzke, Christel Herzog, +5

Journal of Biological Chemistry

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

Ulrich Lücking, Arne Scholz, Philip Lienau, +24

ChemMedChem

The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (<i>R</i>)‐<i>S</i>‐Cyclopropyl‐<i>S</i>‐(4‐{[4‐{[(1<i>R</i>,2<i>R</i>)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer

Ulrich Lücking, Rolf Jautelat, Martin Krüger, +9

ChemMedChem

Aminopyrimidine Zk 304709Lab Oddity PrevailsLead IdentificationBay 1000394Zk 304709 +19